Boehringer Ingelheim – Nintedanib

ANIMA RES produced a 7-minute 3D computer animation film on the mode of action of Nintedanib for Boehringer Ingelheim. Nintedanib is a triple angiokinase inhibitor which also has a direct anti-tumoral effect by inhibiting FGF receptors in addition to its angiogenesis inhibition. Nintedanib is in advanced clinical development for non-small cell lung cancer (NSCLC) and other tumors and is not yet approved.

The primary focus of the mode of action 3D animation film is the simultaneous inhibition of several receptor tyrosine kinases for a greater effect on the tumor angiogenesis, the angiogenic escape mechanism, the central role of VEGF/FGF/PDGF, the vascular re-modelling and the metastasis, as well as the highly complex cross-talk in the tumor environment.


“The ANIMA RES team delved deeply into this topic and the film was very well received by customers. We all really liked the film within the company, and we are very pleased with the result of the long and intensive collaboration.”

Anja Urbanek, Oncology/Virology PM Germany, Boehringer Ingelheim Pharma GmbH & Co. KG